Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Krie and Yuan Talk Toxicity Management in Breast Cancer

August 23rd 2021

Dr. Krie and Dr. Yuan discussed treatment-related adverse effects one should be aware of and prepared to manage, recommended management strategies for these TRAEs, and important points to emphasize to patients before they begin treatment.

Dr. Litton on the Safety of Neoadjuvant Talazoparib in HER2-Negative Breast Cancer

August 23rd 2021

Jennifer Litton, MD, discusses the safety of talazoparib (Talzenna) in the neoadjuvant treatment of patients with germline BRCA1/2-positive, early-stage HER2-negative breast cancer.

Pushing the Boundaries of Personalized Cancer Care

August 21st 2021

When imagining a champion of change, one can easily point to Laura J. van ’t Veer, PhD, the 2020 Giants of Cancer Care® award winner in Cancer Diagnostics, as a prime example.

DFS Benefit Similar With Extended Intermittent or Continuous Letrozole in HR+ Breast Cancer

August 20th 2021

Extended adjuvant endocrine therapy via intermittent administration of letrozole did not improve disease-free survival vs continuous use in postmenopausal patients with hormone receptor–positive breast cancer, but represents a valid approach for those who require or prefer a treatment interruption.

Emerging Combinations for Triple-Positive Breast Cancer

August 17th 2021

An overview of various trials investigating combination approaches as frontline therapy for triple-positive breast cancer and considerations for when to use chemotherapy and bring endocrine therapy into treatment.

Frontline Therapy for Triple-Positive Breast Cancer

August 17th 2021

Vijayakrishna Gadi, MD, PhD, defines triple-positive breast cancer and reacts to the potential use of trastuzumab combined with endocrine therapy as frontline therapy.

Dr. Extermann on Selecting Among Available CDK4/6 Inhibitors in HR+ Breast Cancer

August 16th 2021

Martine Extermann, MD, PhD, shares advice for selecting among the CDK4/6 available for the treatment of patients with hormone receptor–positive breast cancer.

Dr. Sam on Sequencing Tucatinib and Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 16th 2021

Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.

Dr. Carey on the Updated Results of the PALOMA-3 Trial in HR+/HER2- Breast Cancer

August 16th 2021

Lisa A. Carey, MD, FASCO, discusses the updated results of the phase 3 PALOMA-3 trial in hormone receptor–positive, HER2-positive breast cancer.

Dr. Khong on the Importance of BRCA Testing in Breast Cancer

August 16th 2021

Hung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer.

Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer

August 13th 2021

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Making the Most of Molecular Testing in Breast Cancer

August 12th 2021

Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.

Dr. Sam on Therapeutic Developments in Metastatic HER2+ Breast Cancer

August 12th 2021

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

NICE Recommends Abemaciclib for HR+/HER2– Advanced Breast Cancer

August 12th 2021

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance supporting the use of abemaciclib in the treatment of adult patients with metastatic hormone receptor–positive/HER2-negative breast cancer.

Expanding Armamentarium Allows for Tailored Approaches in Breast Cancer, in Especially Older Patients

August 12th 2021

The widening treatment paradigm for various breast cancer subtypes is yielding improved survival with more tailored strategies.

Rapid Readouts: Phase 3 ASCENT Study for Metastatic Triple-Negative Breast Cancer

August 11th 2021

Hope S. Rugo, MD, FASCO, discusses data presented at the 2021 American Society of Clinical Oncology annual meeting from the phase 3 ASCENT study of patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.

Future Directions for the Management of HR+ Breast Cancer

August 11th 2021

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

ES HR+ Breast Cancer: CDK4/6 Inhibitors in Clinical Practice

August 11th 2021

A discussion on the use of adjuvant CDK4/6 inhibitors in clinical practice for the treatment of early stage HR+ breast cancer.

Gaps in Treatment for HER2+ MBC With Brain Metastasis

August 10th 2021

Considerations for addressing gaps in treatment for patients with HER2-positive metastatic breast cancer and brain metastasis, based on recent trial data.

Case Scenario: 55-Year-Old Woman With HER2+ MBC and Brain Metastasis

August 10th 2021

A discussion regarding the preferred treatment approach for a 55-year-old woman with HR-/HER2+ metastatic breast cancer and 2 brain metastases.